Ameriprise
OMED

Ameriprise’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Ameriprise’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-283,220
Closed -$654K – 3863
2018
Q2 		$654K Sell
283,220
-21,100
-7% -$61.4K ﹤0.01% 3165
2018
Q1 		$968K Sell
304,320
-656,817
-68% -$1.81M ﹤0.01% 2984
2017
Q4 		$3.94M Buy
961,137
+49,953
+5% +$217K ﹤0.01% 2291
2017
Q3 		$4.12M Sell
911,184
-55,811
-6% -$226K ﹤0.01% 2226
2017
Q2 		$3.22M Buy
966,995
+286,545
+42% +$1.19M ﹤0.01% 2365
2017
Q1 		$6.27M Buy
+680,450
New +$5.98M ﹤0.01% 1867
2014
Q4 		– Sell
-15
Closed – – 5394
2014
Q3 		$0 Sell
15
-15
-50% -$301 ﹤0.01% 6165
2014
Q2 		$1K Buy
+30
New +$741 ﹤0.01% 5508
2013
Q4 		– Sell
-13,500
Closed -$207K – 5917
2013
Q3 		$207K Buy
+13,500
New +$250K ﹤0.01% 3169

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Ameriprise's OMED Position: Q3 2018 in Review

Ameriprise sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q3 2018, closing a stake of 283,220 shares — an estimated $654K sold.

Ameriprise first reported a position in OMED in Q3 2013 and held it in 9 quarters. The position peaked at $6.27M in Q1 2017. 54 funds tracked by Wall St. Rank hold OMED as of Q3 2018.

  • Ameriprise reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Ameriprise sold 283,220 OncoMed Pharmaceuticals, Inc. shares in Q3 2018, an estimated $654K.
  • Ameriprise first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2013 and held it in 9 quarters.
  • Ameriprise's OncoMed Pharmaceuticals, Inc. position peaked at $6.27M in Q1 2017.
  • 54 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q3 2018.

Based on Ameriprise's 13F filing for Q3 2018, filed 14 Nov 2018.